- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07946926
Adaptation of Facilitated Access to Mutual Aid for Community Alcohol and Drug Services (FAMA)
Adaptation of a Facilitated Access to Mutual Aid (FAMA) Intervention for Adults Accessing Community Alcohol and Drug Services in England.
Alcohol and other drug (AOD) use disorders are associated with a range of adverse outcomes. Relapse following AOD treatment is common. Attendance at Mutual Aid Groups (MAGs) is associated with improved health outcomes and reduced healthcare utilisation costs. National guidance recommends that clinical staff promote MAG attendance, but few patients are referred to, or attend, MAGs. An intensive referral intervention, developed in the United States of America has been shown to increase engagement with MAGs. The aim of this National Institute for Health Research (NIHR)-funded study is to adapt and test a Facilitated Access to Mutual Aid (FAMA) intervention and staff training for delivery in community AOD services in England.
Phase one of this study consists of qualitative focus groups conducted with staff of community AOD services and adults receiving AOD treatment. Eight focus groups will explore participants' views of MAGs and the existing American FAMA intervention. The FAMA intervention will then be adapted and staff training developed, based on the focus group findings and input from patient and public involvement and engagement (PPIE) groups.
Phase two of this study consists of testing the adapted FAMA intervention. Staff in one community AOD service will receive the newly developed FAMA training. They will deliver FAMA to people who are currently receiving AOD treatment service. Each session will be recorded and the fidelity of intervention delivery will be assessed by the research team using a checklist. Staff and patient feedback will be collected using brief questionnaires in informal feedback sessions. The FAMA intervention will be refined and delivered again with another round of feedback being collected. A final version of the FAMA intervention will then be agreed by the research team and PPIE groups.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Adults aged 18+ years who are accessing AOD treatment and staff, aged 18+ years who are working in paid client facing role in an AOD treatment service.
Descrição
Phase one (staff) inclusion criteria:
- Aged 18+ years
- Currently working in a paid client facing role in an AOD treatment service
Phase one (people accessing AOD treatment) inclusion criteria:
- Aged 18+ years
- Currently receiving treatment from an AOD treatment service
Phase two (staff) inclusion criteria:
- Aged 18+ years
- Currently working as a keyworker or recover worker in an AOD treatment service
Phase two (people accessing AOD treatment) inclusion criteria:
- Aged 18+ years
- Currently receiving treatment from an AOD treatment service
- On a participating staff member's caseload
- Not attending MAGs.
Exclusion Criteria:
- N/A
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: CROSS_SECTIONAL
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Qualitative focus groups
Prazo: Focus groups will last approximately 90 minutes
|
Qualitative focus groups |
Focus groups will last approximately 90 minutes
|
|
Acceptability of Intervention measure (AIM) adapted for FAMA
Prazo: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be acceptable |
Maximum 10 weeks from enrolment in the study
|
|
Feasibility of Intervention (FIM) adapted for FAMA
Prazo: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be feasible |
Maximum 10 weeks from enrolment in the study
|
|
Appropriateness Measure (IAM) adapted for FAMA
Prazo: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be appropriate |
Maximum 10 weeks from enrolment in the study
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRAS 370125
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .